novavax applies for EUA

February 1, 2022
Novavax applies for Emergency Use Authorization (EUA) for their COVID-19 vaccine.

We believe our vaccine offers a differentiated option built on a well-understood protein-based vaccine platform that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic.

Novavax CEO Stanley Erck on the company applying for FDA emergency use authorization for their COVID-19 vaccine.
  • Here's the basics on the Novavax vaccine:
    • Two doses given three weeks apart.
    • Clinical studies showed 90%+ efficacy of preventing infection (but this was before Omicron).
    • The vaccine uses more "traditional" vaccine development – using a lab-produced viral particle to stimulate immune response. The mRNA technology used by Pfizer and Moderna essentially provides the body a blueprint of a piece of the coronavirus' unique spike protein, so the body can build the spike protein piece and then produce an immune response against it.
    • Easily stored in regular refrigeration.

Why It Matters: If granted EUA, Novavax provides consumers with another option for a vaccine.

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Novavax seeks FDA emergency use authorization of its coronavirus vaccine

by Jenna Lee,